Drug Trial Data Manipulation Wiped Avacopan’s EU Approval as FDA Hearing Looms
The EMA published an Aug 6, 2026 assessment report detailing alleged manipulation of nine patient records in the ADVOCATE Phase 3 trial of avacopan (Tavneos), after database lock and unblinding. The European Commission revoked EU approval Aug 6, 2026, following a June 25 CHMP recommendation. In the US, the FDA is reviewing Amgen’s July 23 hearing submission to withdraw Tavneos, based on similar data-integrity issues.
How this was made
The 30-second read
Why it matters
The EMA’s August 6 revocation and the FDA’s April 27 NOOH proposal are presented as sharing the same core data-integrity failure. The text emphasizes that regulators rejected the independent re-analysis as a remedy, and it frames the upcoming FDA hearing as a key decision point for US patients and the label.
Market read
This is a regulatory-risk catalyst with a clear US decision timeline into the FDA hearing, anchored by EU revocation and rejection of re-analysis as a cure.
What to watch
The article does not quantify US commercial exposure, potential settlements, or whether the FDA hearing could result in partial label changes; traders may over-discount outcomes without those specifics.
Background
Avacopan (Tavneos) is supported by the ADVOCATE Phase 3 trial; the article centers on alleged post-unblinding record alterations after database lock and the inability to cure GCP violations via re-adjudication.
Ticker impact
The article says EMA revoked avacopan (Tavneos) across the EU after documented database-lock record alterations, and FDA is pursuing a similar withdrawal.
Downward bias for AVAC on any confirmation of US withdrawal trajectory; volatility elevated into the FDA hearing.
The text links EU revocation to the same GCP violation basis cited in the FDA NOOH proposal, and highlights that an independent re-analysis was rejected as a remedy.
The article attributes the FDA hearing submission and the EU revocation context to Amgen’s handling of the avacopan/Tavneos regulatory process.
Negative-to-volatile reaction risk for AMGN as traders price higher probability of US withdrawal or label limitation.
The article states Amgen submitted for an FDA hearing and commissioned an independent re-adjudication, which regulators rejected as insufficient to cure the GCP violation.
Market effects
Raises scrutiny on clinical trial data integrity and the durability of endpoint superiority claims after database-lock contamination.
EU withdrawal signals a stricter European stance that may influence US regulators’ posture in similar GCP cases.
EMA’s detailed public assessment and FDA’s parallel NOOH basis can become a reference template for other regulators and sponsors.
Counterpoint
Amgen’s independent blinded re-adjudication reportedly preserved noninferiority and showed a sustained-remission difference, which could support arguments for a narrower remedy rather than full withdrawal.
Key entities
- drugAvacopan (Tavneos)
C5a receptor blocker whose EU approval was revoked after documented database-lock related record alterations in ADVOCATE.
- companyAmgen
Sponsor in the US regulatory process, submitted for an FDA hearing and commissioned an independent re-adjudication.
- companyChemoCentryx
Named via employees involved in the re-adjudication process after unblinding, tied to the ADVOCATE trial conduct.
- regulatorEuropean Medicines Agency (EMA)
Published the Article 20 Public Assessment Report detailing the rationale for EU withdrawal.
- regulatorFDA
Issued a NOOH proposal and is evaluating withdrawal via a formal hearing submission.
